Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.

Lugaresi, Alessandra

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. [electronic resource] - Clinical neuropharmacology - 167-72 p. digital

Publication Type: Journal Article; Multicenter Study

1537-162X

10.1097/wnf.0b013e3181571a8e doi


Adjuvants, Immunologic--therapeutic use
Disability Evaluation
Dose-Response Relationship, Drug
Humans
Injections, Subcutaneous
Interferon beta-1a
Interferon-beta--therapeutic use
Multiple Sclerosis, Relapsing-Remitting--diagnosis
Patient Satisfaction
Prospective Studies
Recurrence
Self Administration--instrumentation
Severity of Illness Index
Surveys and Questionnaires
Syringes
Treatment Outcome